Phase II study of aminothiadiazole in advanced squamous cell carcinoma of the esophagus

Am J Clin Oncol. 1991 Feb;14(1):33-5. doi: 10.1097/00000421-199102000-00007.

Abstract

Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Allopurinol / administration & dosage
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / secondary
  • Drug Evaluation
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / mortality
  • Female
  • Humans
  • Male
  • Middle Aged
  • Survival Rate
  • Thiadiazoles / administration & dosage*

Substances

  • Antineoplastic Agents
  • Thiadiazoles
  • Allopurinol
  • 2-amino-1,3,4-thiadiazole